Last reviewed · How we verify

NCT07241130

Using End-Tidal CO₂ to Help Diagnose and Monitor Pulmonary Embolism

Completed Last updated 22 December 2025
What this trial tests

trial testing thrombolytic therapy in Pulmonary Embolism Acute in 120 participants. Completed in 30 July 2025.

Timeline
1 February 2025
Primary endpoint
30 July 2025
30 July 2025

Quick facts

Lead sponsorAtaturk University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment120
Start date1 February 2025
Primary completion30 July 2025
Estimated completion30 July 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ataturk University

Who can join

Adults 18 to 80, any sex, with Pulmonary Embolism Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pulmonary embolism (PE) can reduce blood flow in the lungs and impair gas exchange, leading to lower end-tidal carbon dioxide (EtCO₂) levels. This prospective observational study aims to evaluate whether EtCO₂ can help identify high-risk and intermediate-high-risk patients and monitor early treatment response, especially during thrombolytic therapy. A total of 120 participants were included: high-risk PE, intermediate-high-risk PE patients who received thrombolysis, intermediate-high-risk PE patients treated only with anticoagulation, and healthy controls. The study measured EtCO₂ along with oxygen saturation, heart rate, respiratory rate, perfusion index, and radiological obstruction scores. By comparing these parameters at diagnosis and during the first 24 hours, the study seeks to determine whether EtCO₂ can serve as a simple, noninvasive marker of disease severity and early hemodynamic improvement in patients with acute PE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pulmonary Embolism Acute

Currently open trials in the same condition.

Other Ataturk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07241130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing